Findings

What do systematic reviews say?

14 questions · 14 findings · 3 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 14.3%GRADE not reported 0 · 0%Very low 9 · 64.3%Low 3 · 21.4%Moderate 0 · 0%High 0 · 0%

DFX film‐coated tablet vs DFX dispersible tablet

All‐cause mortality

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
7.3 [0.14, 368.15]
1 study · 173 participants
Very low

DFP and DFO vs DFP

All‐cause mortality

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
0.77 [0.17, 3.42]
2 studies · 237 participants
Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

All‐cause mortality

It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes all‐cause mortality compared with deferoxamine (DFO) (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RR 0.47 [0.18, 1.21]
3 studies · 376 participants
Very low

DFP and DFO vs deferoxamine

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs deferiprone (DFO)

All‐cause mortality

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
0.96 [0.06, 15.42]
2 studies · 240 participants
Very low

Hydroxyurea vs placebo

All‐cause mortality · people with sickle cell disease

1 finding from 1 review · compare the 2 reviews

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 193 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

All‐cause mortality · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Transfusions continued vs transfusions halted

All‐cause mortality · prevention of SCI in people with SCD and normalised TCD velocities

It is very uncertain whether transfusions continued changes all‐cause mortality compared with transfusions halted (very low certainty).

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
Peto OR 8 [0.16, 404.12]
1 study · 79 participants
Very low

Long‐term red cell transfusion vs usual care

All‐cause mortality · prevention of SCI in people with SCD and normal TCD velocities

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 196 participants
Low

Hydroxyurea vs RBC transfusion

All‐cause mortality · prevention of SCI in people with SCD who have not had a stroke (primary prevention)

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Hydroxyurea vs RBC transfusion

All‐cause mortality · prevention of SCI in people with SCD who had a stroke (secondary prevention)

It is very uncertain whether hydroxyurea changes all‐cause mortality compared with RBC transfusion (very low certainty).

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
OR 1.02 [0.06, 16.41]
1 study · 133 participants
Very low

Long‐term red cell transfusion vs usual care

All‐cause mortality · prevention of SCI in people with SCD and abnormal TCD velocities

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 130 participants
Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

All‐cause mortality (n/N)

Summary of findings: Comparison 3 ‐ deferiprone (DFP) showed no clear difference in all‐cause mortality (n/N) compared with deferasirox (DFX) (low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RD 0
1 study · 390 participants
Low

It is very uncertain whether summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… changes all‐cause mortality ‐ at 1 year ‐ trial end compared with DFP plus deferasirox (DFX) (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RD 0
1 study · 96 participants
Very low